Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS |
Hidradenitis Suppurativa | Phase3 | Argentina Australia |
NCT07665437 |
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) | Phase3 | Argentina Australia China India Malaysia South Korea Switzerland United States View all |
NCT07357727 |
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) |
Cardiovascular Disease and Lipoprotein(a) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria Canada China Colombia Czechia Denmark France Germany Greece Hong Kong Hungary Iceland India Israel Italy Japan Netherlands Norway Poland Puerto Rico Romania Russia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT07517263 |
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease |
Huntington Disease | Phase3 | Argentina Australia Canada China France Israel South Korea Switzerland Taiwan United Kingdom United States View all |
NCT07326709 |
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis |
Secondary Progressive Multiple Sclerosis (SPMS) | Phase3 | Argentina Australia Austria Belgium Brazil Bulgaria Canada China Colombia Croatia Czechia Denmark Estonia France Germany Greece Hungary India Israel Italy Lithuania Mexico Netherlands Poland Portugal Romania Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT07225504 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
Relapsing Multiple Sclerosis | Phase3 | Argentina Australia Belgium Brazil Canada Czechia Denmark France Germany Greece Italy Mexico Portugal Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT06846281 |
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. |
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease | Phase3 | Argentina Australia Canada Malaysia South Korea United States View all |
NCT06858319 |
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN |
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase2 | Argentina Israel Malaysia Saudi Arabia United States View all |
NCT06797518 |
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis |
Atopic Dermatitis | Phase2 | Argentina Canada China Czechia France Germany Hungary Italy Japan Netherlands Poland Slovakia South Korea Spain Taiwan United Kingdom United States View all |
NCT06947993 |
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. |
Chagas Disease | Phase2 | Argentina Brazil Colombia United States View all |
NCT06632600 |